Previous 10 | Next 10 |
Shares of Prometheus Biosciences (NASDAQ: RXDX) nearly tripled on Wednesday, Dec. 7, 2022. Investors were cheering for some surprisingly good news regarding the clinical-stage biotechnology company's lead candidate. Prometheus Biosciences' stock price rocketed higher thanks to signs t...
Prometheus Biosciences ( NASDAQ: RXDX ) has priced an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110/share, for an expected gross proceeds of $500M. All of the shares to be sold in the offering are to be sold by Prometheus. Offer...
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treat...
Summary On December 7, Prometheus Biosciences, Inc. announced positive Phase 2 data for PRA023. Prometheus also announced a proposed Public Offering. PRA023 and the pipeline are promising, but risks remain for Prometheus, and competition is intense. Prometheus Biosciences,...
Prometheus Biosciences (NASDAQ: RXDX) saw its shares rise this week as much as 168.7% by early Thursday, according to data from S&P Global Intelligence . The clinical-stage biotech focuses on inflammatory bowel disease (IBD) treatments and immune-related diseases. The stock, a...
Palm Beach, FL – December 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which exceeded USD 25.5 billion in 2021, is estimated to register around 8% CAGR betw...
Biotechnology company Prometheus Biosciences ( NASDAQ: RXDX ) intends to offer and sell $250M of shares in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the public offeri...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Prometheus Biosciences (NASDAQ: RXDX) Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies” Prometheus Biosciences, Inc. (...
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: DANIEL CONSTANTE / Shutterstock Pinterest (NYSE: PINS ) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P. According to a press release, this deal...
News, Short Squeeze, Breakout and More Instantly...
Prometheus Biosciences Inc. Company Name:
RXDX Stock Symbol:
NASDAQ Market:
Prometheus Biosciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...